HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation

Increasing fetal hemoglobin (HbF) provides clinical benefit in patients with sickle cell disease (SCD). We recently identified heme-regulated inhibitor (HRI, EIF2AK1), as a novel HbF regulator. Because HRI is an erythroid-specific protein kinase, it presents a potential target for pharmacologic inte...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood Adv
Main Authors: Peslak, Scott A., Khandros, Eugene, Huang, Peng, Lan, Xianjiang, Geronimo, Carly L., Grevet, Jeremy D., Abdulmalik, Osheiza, Zhang, Zhe, Giardine, Belinda M., Keller, Cheryl A., Shi, Junwei, Hardison, Ross C., Blobel, Gerd A.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2020
主題:
Red Cells, Iron, and Erythropoiesis
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509868/
https://ncbi.nlm.nih.gov/pubmed/32956454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002475
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍